首页> 外文OA文献 >Gene mutations in stool from gastric and colorectal neoplasia patients by next-generation sequencing
【2h】

Gene mutations in stool from gastric and colorectal neoplasia patients by next-generation sequencing

机译:下一代测序技术检测胃和大肠肿瘤患者粪便中的基因突变

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

AIM To study cancer hotspot mutations by next-generation sequencing (NGS) in stool DNA from patients with different gastrointestinal tract (GIT) neoplasms. METHODS Stool samples were collected from 87 Finnish patients diagnosed with various gastric and colorectal neoplasms, including benign tumors, and from 14 healthy controls. DNA was isolated from stools by using the PSP (R) Spin Stool DNA Plus Kit. For each sample, 20 ng of DNA was used to construct sequencing libraries using the Ion AmpliSeq Cancer Hotspot Panel v2 or Ion AmpliSeq Colon and Lung Cancer panel v2. Sequencing was performed on Ion PGM. Torrent Suite Software v.5.2.2 was used for variant calling and data analysis. RESULTS NGS was successful in assaying 72 GIT samples and 13 healthy controls, with success rates of the assay being 78% for stomach neoplasia and 87% for colorectal tumors. In stool specimens from patients with gastric neoplasia, five hotspot mutations were found in APC, CDKN2A and EGFR genes, in addition to seven novel mutations. From colorectal patients, 20 mutations were detected in AKT1, APC, ERBB2, FBXW7, KIT, KRAS, NRAS, SMARCB1, SMO, STK11 and TP53. Healthy controls did not exhibit any hotspot mutations, except for two novel ones. APC and TP53 were the most frequently mutated genes in colorectal neoplasms, with five mutations, followed by KRAS with two mutations. APC was the most commonly mutated gene in stools of patients with premalignant/benign GIT lesions. CONCLUSION Our results show that in addition to colorectal neoplasms, mutations can also be assayed from stool specimens of patients with gastric neoplasms.
机译:目的通过下一代测序(NGS)研究来自不同胃肠道(GIT)肿瘤患者粪便DNA的癌症热点突变。方法从87名被诊断患有各种胃和大肠肿瘤(包括良性肿瘤)的芬兰患者和14名健康对照中收集粪便样本。使用PSP Spin Stool DNA Plus Kit从粪便中分离DNA。对于每个样品,使用Ion AmpliSeq癌症热点面板v2或Ion AmpliSeq结肠癌和肺癌面板v2,将20 ng DNA用于构建测序文库。在离子PGM上进行测序。 Torrent Suite Software v.5.2.2用于变量调用和数据分析。结果NGS成功地检测了72个GIT样本和13个健康对照,胃瘤的成功率为78%,大肠肿瘤的成功率为87%。在患有胃肿瘤的患者的粪便标本中,除了七个新突变外,在APC,CDKN2A和EGFR基因中发现了五个热点突变。从大肠癌患者中,在AKT1,APC,ERBB2,FBXW7,KIT,KRAS,NRAS,SMARCB1,SMO,STK11和TP53中检测到20个突变。除两个新突变外,健康对照未显示任何热点突变。 APC和TP53是大肠肿瘤中最常见的突变基因,具有五个突变,其次是具有两个突变的KRAS。 APC是恶性/良性GIT病变患者粪便中最常见的突变基因。结论我们的结果表明,除结直肠肿瘤外,还可以从胃肿瘤患者的粪便标本中检测突变。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号